SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

Ripple's XRP is trending as the community closely monitors legislative developments regarding the Crypto Clarity Act, with intense debate over whether potential regulatory progress will serve as a catalyst for growth or remain a non-event. Traders are actively discussing the impact of institutional adoption, the influence of broader market movements in Bitcoin, and the ongoing tension between optimistic retail long-term holders and vocal skeptics predicting further price consolidation.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius is experiencing heightened volatility and intense community debate as investors react to a recent influx of analyst price target adjustments and broader concerns over international regulatory shifts. Market participants are actively split between those aggressively adding to positions in anticipation of a potential earnings-driven rebound and others citing increased competition and integration challenges as reasons for caution.

Maase, Inc. operates as a integrated provider and operator of artificial intelligence (AI) centric full-scene digital systems. The firm focus on areas of flexible energy deployment and intelligent commercial network operation, and provide closed-loop solutions from computing infrastructure, smart hardware and full-scene services, aiming to achieve large-scale implementation of AI technologies across industries. The company was founded by Hai Feng Yu on August 6, 2018 and is headquartered in Qingdao, China.

Maase Inc. - Ordinary Shares - Class A

Highest Performances Holdings Inc. - ADR

MAAS is trending as investors react to a strategic pivot toward full-stack enterprise AI, highlighted by the recent signing of a 10M RMB contract and the divestiture of non-core assets to fund high-margin AI infrastructure. The community is actively debating the company's transition from a legacy business to an integrated AI provider, with discussions focused on whether its 7-8 week delivery timeline for custom LLM platforms will serve as a definitive proof-of-concept to justify a significant valuation re-rate.

Northrop Grumman Corp. engages in the provision of advanced aircraft systems. It operates through the following segments: Aeronautics Systems, Defense Systems, Mission Systems, and Space Systems. The Aeronautics Systems segment is involved in the design, development, production, integration, sustainment, and modernization of advanced aircraft systems for the U.S. Air Force, the U.S. Navy, other U.S. government agencies, and international customers. The Defense Systems segment includes integrated battle management systems, weapons systems and aircraft, and mission systems sustainment and modernization. The Mission Systems segment offers advanced mission solutions and multifunction systems, primarily for the U.S. defense and intelligence community, and international customers. The Space Systems segment delivers end-to-end mission solutions through the design, development, integration, production and operation of space, missile defense, launch and strategic missile systems for national security, civil government, commercial, and international customers. The company was founded by John K. Northrop, Thomas V. Jones, and Kent Kresa in 1939 and is headquartered in Falls Church, VA.

Northrop Grumman Corp.

Northrop Grumman is trending as investors weigh strong fundamental demand driven by defense budget tailwinds against market anxiety surrounding potential policy shifts on executive compensation and shareholder distributions. Community sentiment remains polarized, with many traders viewing recent price volatility as a buying opportunity for a core defense asset, while others express frustration over the stock's sensitivity to macroeconomic headlines and sector rotation.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is trending as investors rotate into high-conviction healthcare leaders amid broader market volatility, fueled by strong momentum in its GLP-1 obesity franchise and the company's aggressive expansion through strategic acquisitions. The community is actively discussing the stock's resilient relative strength, upcoming earnings expectations, and potential for further growth as manufacturing capacity scales to meet substantial global demand.

Vicor Corp. engages in the design, development, manufacture, and marketing of modular power components. The firm provides complete power systems based upon a portfolio of patented technologies. Its products include AC-DC converters, power systems, and accessories. The company was founded by Patrizio Vinciarelli in 1981 and is headquartered in Andover, MA.

Vicor Corp.

Vicor Corp. is experiencing intense volatility as investors react to its recent quarterly earnings report, which highlighted a substantial earnings beat but triggered concerns regarding weak backlog growth. The community remains divided, with bulls pointing to the company's long-term potential in AI power infrastructure and licensing, while bears express skepticism over valuation and management's ability to navigate current demand trends.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull Corp is trending as investors monitor a potential breakout above key technical resistance levels, fueled by a combination of strong institutional accumulation and active community discussions regarding its long-term growth potential. While some participants are closely tracking monthly operating metrics and analyst price target upgrades, others remain skeptical, citing historical volatility and concerns over broader market influence.

Adobe, Inc. is a global technology company, which engages in the provision of digital marketing and media solutions. It operates through the following segments: Digital Media, Digital Experience, and Publishing and Advertising. The Digital Media segment offers products and services that enable individuals, teams, businesses, and enterprises to create, publish, and promote content anywhere and accelerate productivity by transforming view, share, engage with and collaborate on documents and creative content. The Digital Experience segment focuses on integrated platform and set of products, services, and solutions that enable businesses to create, manage, execute, measure, monetize, and optimize customer experiences that span from analytics to commerce. The Publishing and Advertising segment includes legacy products and services that address diverse market opportunities, including eLearning solutions, technical document publishing, web conferencing, document and forms platform, web app development, high-end printing, and Adobe Advertising offerings. The company was founded by Charles M. Geschke and John E. Warnock in December 1982 and is headquartered in San Jose, CA.

Adobe Inc

Adobe is trending as investors debate the impact of generative AI on its creative software dominance, following a Morgan Stanley downgrade to Underweight that cited mounting execution risks and a shift in enterprise spending. While some traders view the resulting price volatility as a compelling value opportunity, others in the community remain skeptical, expressing concerns over the company's competitive moat against emerging AI-native tools.

Fortinet, Inc. provides cybersecurity solutions to a variety of businesses, such as enterprises, communication service providers, government organizations, and small to medium-sized businesses. Its product portfolio includes network security, secure access service edge, enterprise networking, security operations, application security, and operational technology. The company was founded by Ken Xie and Michael Xie in November 2000 and is headquartered in Sunnyvale, CA.

Fortinet Inc

Fortinet is trending following a strategic expansion of its partnership with Intel to develop the next-generation SP6 security processor, a move the community views as a significant boost to its custom silicon roadmap. Investors and analysts are actively discussing the stock's bullish technical momentum and strong enterprise demand, with many viewing the company as a key beneficiary of rising AI-driven cybersecurity needs.

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.

Abeona Therapeutics Inc

Abeona Therapeutics is currently trending as investors focus on the commercial ramp-up of ZEVASKYN, highlighted by the recent activation of a fifth Qualified Treatment Center in New York. The community is actively debating the company's path to profitability, weighing the slow initial patient uptake against strong payer coverage and the potential for a breakout as the firm scales manufacturing and expands its treatment network.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Strength Seen in Aclaris (ACRS): Can Its 5.4% Jump Turn into More Strength?

Aclaris (ACRS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Aclaris Therapeutics, Inc. (ACRS): A Top Penny Stock in Investors Portfolio That Stifel is Bullish On

Aclaris Therapeutics, Inc. (ACRS): A Top Penny Stock in Investors Portfolio That Stifel is Bullish On...

Aclaris Therapeutics (ACRS) Reports Q1 Loss, Beats Revenue Estimates

Aclaris (ACRS) delivered earnings and revenue surprises of +7.24% and +46.12%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Aclaris Therapeutics (NASDAQ:ACRS) Stock Rating Upgraded by Guggenheim

Guggenheim upgraded Aclaris Therapeutics to a "strong-buy" rating in a research report on Monday...

Rigel Pharmaceuticals (RIGL) Lags Q1 Earnings and Revenue Estimates

Rigel (RIGL) delivered earnings and revenue surprises of -40.54% and -2.39%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Aclaris Therapeutics Updates ATI-052 Phase 1 Data, Picks ATI-2138 for Phase 2b in Lichen Planus

Aclaris Therapeutics (NASDAQ:ACRS) provided a clinical program update on Tuesday, highlighting full top-line results from its phase I-A single-ascending dose (SAD) and multiple-ascending dose (MAD...

Aclaris Therapeutics (NASDAQ:ACRS) Major Shareholder Sells $1,359,000.00 in Stock

Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) major shareholder Braden Michael Leonard sold 300,000 shares of Aclaris Therapeutics stock in a transaction on Thursday, April 23rd. The...

Aclaris Therapeutics (NASDAQ:ACRS) Major Shareholder Braden Michael Leonard Sells 300,000 Shares

Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) major shareholder Braden Michael Leonard sold 300,000 shares of the stock in a transaction on Thursday, April 23rd. The shares were sold at...

Aclaris Therapeutics (NASDAQ:ACRS) Shares Gap Down - Here's What Happened

Aclaris Therapeutics (NASDAQ:ACRS) Shares Gap Down - Time to Sell...

Aclaris Therapeutics Touts ATI-052 Potential for 3-Month Dosing, More Phase 1 Data Incoming

Aclaris Therapeutics (NASDAQ:ACRS) used an H.C. Wainwright inflammatory skin diseases conference fireside chat to outline development plans and differentiation points for its lead biologic candidate...

Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Wayne, PA.

Aclaris Therapeutics Inc

Aclaris Therapeutics Stock Surges On Licensing Deal, $80 Million Private Placement: Retail Sentiment Jumps

Equity

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.16	--	--	N/A
Q1 '26	-$0.16	-$0.15	4.93%	BEAT
Q4 '25	-$0.14	-$0.16	-10.55%	MISSED
Q3 '25	-$0.14	-$0.12	11.86%	BEAT
Q2 '25	-$0.13	-$0.13	2.15%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

ACRSAclaris Therapeutics Inc

Upcoming Earnings: Q2 '26

Historical Earnings

Latest ACRS News